Cough resident survival guide (pediatrics): Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(104 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link=Cough resident survival guide (pediatrics)]]|| <br> || <br>
| [[Cough resident survival guide (pediatrics)|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}


{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0" ;
{{CMG}} {{AE}} {{Maysoon}},{{TAM}}, {{Hudakarman}}
 
{{SK}} Cough in childhood, Cough in children, An approach to cough in children
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 0 0 10px 10px;" cellpadding="0" cellspacing="0";
|-
|-
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align="center" |{{fontcolor|#2B3B44|Cough resident survival guide (pediatrics) Microchapters}}
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align=center| {{fontcolor|#2B3B44|Cough resident survival guide (pediatrics) Microchapters}}
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Overview|Overview]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Overview|Overview]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Causes|Causes]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Causes|Causes]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#FIRE: Focused Initial Rapid Evaluation|FIRE]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Complete Diagnostic Approach|Diagnosis]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Complete Diagnostic Approach|Diagnosis]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Treatment|Treatment]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Treatment|Treatment]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Do's|Do's]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Do's|Do's]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Cough resident survival guide (pediatrics)#Don'ts|Don'ts]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" |[[Cough resident survival guide (pediatrics)#Don'ts|Don'ts]]
|}
|}
==Overview==
==Overview==
Cough in kids is one of the most common presenting complaint to pediatricians. importantly cough is not disease by itself but rather a manifestation of underlying pathology.
A cough is protective action and can be initiated both voluntary and via stimulation of cough respiratory located throughout the respiratory tract (ear – sinus – upper and lower airway )
==Classification==
======Cough is usually classified based on======
1.Duration:
- acute< 2 weeks
- Subacute 2 – 4 weeks
- Chronic > 4 weeks
2.Etiology:
- Specific
-  Not specific
3. Quality:
- Dry cough
 - Wet (moist) cough 


4. Timing:
[[Cough]] is a sudden, often repetitive, [[spasm]]odic contraction of the [[thoracic cavity]], resulting in a violent release of air from the [[lungs]], and usually accompanied by a distinctive sound. A [[cough]] by itself is not a complete diagnosis but rather a symptom of an underlying condition, despite this, it accounts as one of the most common indications for visits to the general practitioners and family physicians with a good proportion of these cases resulting in a pulmonology referral.
 
Coughing is an action the body takes to get rid of substances that are irritating the air passages. The act of coughing can be triggered by a myriad of conditions [[physiologic]] and otherwise. A cough is mostly initiated to clear a buildup of [[phlegm]] within the [[vertebrate trachea|trachea]]. Coughing can also be triggered by a [[Bolus (digestion)|bolus]] of food entering the trachea and other parts of the respiratory tree rather than the [[esophagus]] due to a failure of the [[epiglottis]] function.
- Nocturnal cough
 
- Seasonal/ geographical variation 


==Causes==
==Causes==
 
===Life Threatening Causes===
===Life Threatening causes===
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated:
 
* [[Pulmonary embolism]] <ref name="pmid21530139">{{cite journal| author=Patocka C, Nemeth J| title=Pulmonary embolism in pediatrics. | journal=J Emerg Med | year= 2012 | volume= 42 | issue= 1 | pages= 105-16 | pmid=21530139 | doi=10.1016/j.jemermed.2011.03.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21530139  }} </ref>
*Congestive heart failure
* [[Pneumonia]] <ref name="pmid12093940">{{cite journal| author=Tan TQ, Mason EO, Wald ER, Barson WJ, Schutze GE, Bradley JS | display-authors=etal| title=Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. | journal=Pediatrics | year= 2002 | volume= 110 | issue= 1 Pt 1 | pages= 1-6 | pmid=12093940 | doi=10.1542/peds.110.1.1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12093940  }} </ref>
*Pneumonia
* [[Asthma|Acute exacerbation of asthma]] <ref name="urlAcute Asthma: Observations Regarding the Management of a Pediatric Emergency Room | American Academy of Pediatrics">{{cite web |url=https://pediatrics.aappublications.org/content/83/4/507 |title=Acute Asthma: Observations Regarding the Management of a Pediatric Emergency Room &#124; American Academy of Pediatrics |format= |work= |accessdate=}}</ref>
*Acute inhalation injury
*Acute exacerbation of asthma/COPD


===Common Causes===
===Common Causes===


====Noninfectious causes====
{| class="wikitable" border="1"
 
!style="width: 300px;background:#4479BA"|{{fontcolor|#FFF| '''Acute cough (less than 3 weeks)'''<ref name="urlwww.ncbi.nlm.nih.gov">{{cite web |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056681/pdf/0570315.pdf |title=www.ncbi.nlm.nih.gov |format= |work= |accessdate=}}</ref>}} !!style="width: 300px;background:#4479BA"|{{fontcolor|#FFF| '''Subacute (3 to 8 weeks) or chronic cough (3 to 4 months)'''<ref name="pmid14586058">{{cite journal| author=de Jongste JC, Shields MD| title=Cough . 2: Chronic cough in children. | journal=Thorax | year= 2003 | volume= 58 | issue= 11 | pages= 998-1003 | pmid=14586058 | doi=10.1136/thorax.58.11.998 | pmc=1746521 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14586058  }} </ref>}}
#Asthma
|-
#Gastroesophageal reflux disease
| valign="top" |
#Forgein-body aspiration
* [[Common cold]]
#Upper-airway cough syndrome
* [[Bronchitis]] or [[Bronchiolitis]]
#Extrinsic airway compression
* [[Asthma]]
#Smoking  (active or passive)
* [[Pertussis]]
#Cystic fibrosis
* [[Croup]]
#Interstitial lung disease
* [[Influenza]]
#Nonasthmatic eosinophilic bronchitis
* [[Foreign body]]
 
* [[Pneumonia]]
10. Congenital defects (.g., esophageal atresia with/without tracheoesophageal fistula, vascular rings) <br />
* [[Second-hand smoke]]
 
* [[Gastroesophageal reflux disease|Gastroesophageal reflux disease (GERD)]] <ref name="urlwww.ncbi.nlm.nih.gov">{{cite web |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056681/pdf/0570315.pdf |title=www.ncbi.nlm.nih.gov |format= |work= |accessdate=}}</ref>
====Infectious causes====
| valign="top" |
Isolated cough: otherwise healthy child
* [[Bronchitis|Recurrent viral bronchitis]]
* [[PND|Postnasal dribbling]]
* [[asthma|Cough variant asthma]]
* [[Psychogenic|Psychogenic cough]]
** Habit cough (tic like)
** Bizarre honking cough
* [[Gastroesophageal reflux|Gastroesophageal reflux]]
* [[Cystic fibrosis]]
* [[Foreign body|Retained foreign body]]
* [[Primary ciliary dyskinesia]]
* [[Immune deficiency|Immune deficiencies]]
* [[Chronic bronchitis]]
* Airway lesions
** Compression, e.g. tuberculous gland
** Malacia, often with viral infection, e.g. [[Tracheoesophageal fistula |Tracheoesophageal fistula cough]] <ref name="pmid14586058">{{cite journal| author=de Jongste JC, Shields MD| title=Cough . 2: Chronic cough in children. | journal=Thorax | year= 2003 | volume= 58 | issue= 11 | pages= 998-1003 | pmid=14586058 | doi=10.1136/thorax.58.11.998 | pmc=1746521 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14586058  }} </ref>
|}


#Chronic sinusitis with upper-airway cough syndrome
==Diagnosis==
#Pyogenic bacterial pneumonia
The approach to diagnosis of [[Cough]] in children is based on a step-wise testing strategy. Below is an algorithm summarising the identification and laboratory diagnosis of [[Cough]].<ref name="pmid28860265">{{cite journal| author=Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S | display-authors=etal| title=Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. | journal=Eur Respir J | year= 2017 | volume= 50 | issue= 2 | pages=  | pmid=28860265 | doi=10.1183/13993003.02426-2016 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28860265  }} </ref><ref name="pmid26483178">{{cite journal| author=Weinberger M, Hoegger M| title=The cough without a cause: Habit cough syndrome. | journal=J Allergy Clin Immunol | year= 2016 | volume= 137 | issue= 3 | pages= 930-1 | pmid=26483178 | doi=10.1016/j.jaci.2015.09.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26483178  }} </ref>
#Prolonged bacterial bronchitis
#Tuberculosis
#Mycoplasma pnumoniae infection
#Chlamydophila pneumoniae infection
#Pertussis
#Respiratory viral infections (influenza, adenovirus, rhinovirus, respiratory syncytial virus, parainfluenza virus


==FIRE: Focused Initial Rapid Evaluation==
{{familytree/start |summary=PE diagnosis Algorithm.}}
<br />
{{familytree | | | | | | | | A01 | | | A01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''[[Cough]]'''</div>}}
 
{{familytree | | | | | | | | |!| | | | }}
==Complete Diagnostic Approach==
{{familytree | | | | | | | | B01 | | | B01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Characterize the symptoms'''<br> ❑  [[productive cough|Chronic wet/productive cough]]<br> ❑ [[Chest pain]]<BR> ❑ [[Foreign body aspiration|History suggestive of inhaled foreign body]] <br> ❑ [[dyspnea|Dyspnea]]<br> ❑ [[exertional dyspnea|Exertional dyspnea]]<br> ❑ [[Hemoptysis]]<br> ❑ [[Failure to thrive]]<br> ❑ [[Choking]]<br> ❑ [[Vomiting]]<br> ❑ [[Tetralogy of Fallot|Cardiac anomaly]]<br> ❑ [[Neurodevelopmental Disorders|Neurodevelopmental abnormalities]] <br> ❑ [[Respiratory infections|Recurrent sinopulmonary infections]]<br> ❑ [[Immunodeficiency]]<br> ❑ [[Tuberculosis|Epidemiologic risk factors for exposure to TB]]</div>}}
1.  '''Characterized of cough'''  
{{familytree | | | | | | | | |!| | | | }}
 
{{familytree | | | | | | | | C01 | | | C01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Examine the patient'''<br> ❑  [[Respiratory distress]]<br> ❑ [[Digital clubbing]]<BR> ❑  [[Chest wall deformities|Chest wall deformity]] <br> ❑ [[Crackles|Auscultatory crackles]]</div>}}
 
{{familytree | | | | | | | | |!| | | | }}
- Onset                A)sudden
{{familytree | | | | | | | | D01 | | | D01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''Order [[Chest X-ray]] or [[spirometry]] (if child is able to perform)'''</div>}}
 
{{familytree | | | |,|-|-|-|-|^|-|-|-|-|.| | }}
                            B) gradual (chronic lung diseases )
{{familytree | | | E01 | | | | | | | | F02 | E01=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''[[Productive cough|Wet Cough or Productive Cough with sputum]]'''| F02=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''[[Dry Cough]]'''</div>}}
 
{{familytree | | | |!| | | | | |,|-|-|-|+|-|-|-|.| | }}
 
{{familytree | | | G01 | | | | H01 | | H02 | | H03 |G01=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Consider the diagnosis of [[Bronchitis|Bacterial bronchitis]]'''| H01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Consider the diagnosis of [[Asthma]]'''<br> ❑  History of bilateral [[wheeze]] and [[exertional dyspnea]] <br> ❑ Absence of other [[Cough|cough symptoms]]<BR> ❑  Absence of findings on lung examination<br> ❑ [[Asthma|Reversible obstructive defect]] or normal finding on [[spirometry]] (if performed)|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Consider the diagnosis of [[Foreign body aspiration|Retained foreign body]]'''<br> ❑ History of choking or sudden onset of symptoms<br> ❑ Monophonic or unilateral wheeze<BR> ❑ Chest X-ray finding suggesting [[foreign body]]|H03=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Consider the other type of [[cough]]'''<br> ❑ [[Tracheomalacia]]<br> ❑ [[Pertussis]]<BR> ❑ [[Tic |Habit cough/ tic cough]] (typically absent at night or when distracted and may be honking or short/dry)</div>}}
 
{{familytree | | | |!| | | | | |!| | | |!| | | |!| | }}
- Duration            A(acute  2 weeks - URTI -  bronchiolitis
{{familytree | | | I01 | | | | I02 | | I03 | | I04 |I01=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Antibiotics for 2 to 4 weeks'''|I02=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Trial of [[Asthma]] therapies for 2 to 4 weeks'''|I03=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Perform [[Bronchoscopy|rigid bronchoscopy]] for [[Foreign body|foreign body removal]]'''|I04=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Perform tests to confirm the diagnosis and treat as appropriate'''</div>}}
 
{{familytree | |,|-|^|-|.| | | |!| | | |!| | | | | | | }}
                             B) subacute ( 2 – 4 ) weeks
{{familytree | J01 | | J02 | | J03 | | J04 |J01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''[[Cough]] resolves'''<br> ❑ Likely [[Bronchitis|bacterial bronchitis]]<br> ❑ Reassess in 3 to 4 months to confirm that child remains well|J02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Productive cough continues after 4 weeks'''<br> ❑ Consider the diagnosis of:
 
* [[Tuberculosis]]
             C) chronic > 4 weeks – cystic fibrosis
* [[Ciliary dyskinesia|Primary ciliary dyskinesia]]
 
* [[Cystic fibrosis]]
 
* [[Bronchiectasis]]|J03=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''[[Asthma]] Improved'''<br> ❑ Continue treatment<br> '''[[Asthma]] not improved'''<br> ❑ Reassess for other causes of [[cough]]|J04=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''No [[foreign body]]'''<br> ❑ Reassess for other causes of [[cough]]</div>}}
 
{{familytree/end}}
                       - Quality               A) wet (moist)  - bronchiectasis
 
                                            B) dry cough
 
                      - Worsening and relieving factor
 
                      - Diurnal         A) night – Asthma
 
                                        B) only day habits cough
 
                       - certain characterized        A) brassy cough (barking)  croup
 
                                                                      B) paroxysmal  pertussis
 
                                                                       C) staccato chlamydia
 
                                                                       D) honking   - habits cough
 
 
 
2 '''. characterized associated symptoms'''  
 
non specific   -   sweating -  lethargy    -   headache    -   vomiting
 
 
'''3. cardiac symptoms'''  
 
                            Chest pain -  palpitation  -     oedema   - exertional dyspnea
 
 
'''4. symptoms  suggestive pulmonary problem'''
 
                                 Dyspnea   -  hemoptysis    -  grunting   -   pleural pain
 
 
'''5. symptoms suggestive gastrointestinal etiology'''
 
Burn sensation (GERD)- epigastric pain  -   Regurgitation
 
                 Choking (tracheoesophageal  fistula )
 
 
'''6. inquired about medical history'''
 
- previous episode of cough
 
-  past history of asthma  -allergic rhinitis ,eczema
 
-  Family history of lung or allergic smoking,  asthma
 
 
'''7.examine the patient'''  
 
-  general appearance  -  cyanosis -  pallor  - jaundice -  -  nail  clubbing
 
- general examination
 
-Inspect nose if there are any polyps (cystic febrosis) , skin rash
 
-Vital signs  -  heart rate -   respiration rate  - blood pressure ---
 
Pulse;  pulsus-severe asthma
 
-  Chest      A) any deformity
 
                  B) auscultation; symmetrical  air entery  crepitation – wheezing (asthma )
 
-Heart sounds;  S1 – S2   -S3 or murmur
 
 
'''8. order labs  - tests according to the suspected etiology'''
 
 
-  CBC-  CRP -  ESP
 
- SPUTUM CULTURE
 
- SWEAT TEST (CYSTIC FEBROSIS)
 
- LIPASE – AMYLASE EN TYME (CYSTIC FEBROSIS)
 
- ABG
 
- MANTOUX TEST FOR TB
 
 
'''9. order Imaging study'''
 
- CXR  A)  consolidation pneumonia
 
               B) pleural effusion
 
                C) pneumothorax
 
- Echocardiography to rule out any heart diseases
 
-Pulmonary function test


==Treatment==
==Treatment==
Shown below is an algorithm summarizing the treatment of underlying conditions that cause [[cough]].


Once the history and physical examination have led to an initial assessment, the fact that
===Acute cough===
 
{{familytree/start |summary=PE diagnosis Algorithm.}}
cough is a symptom of an underlying condition should be discussed with the patient and
{{familytree | | | | | | | | | | | | | A01 |A01=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Treat the underlying causes'''}}
 
{{familytree | | | | | | | | | | | | | |!| | | | | | }}
family. Treatment of the underlying disorder (if necessary) should always be the prime
{{familytree | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| }}
 
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | }}
focus.Empiric therapy, based on primary assessment, can be a reasonable starting point.
{{familytree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | C07 |C01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Bronchiolitis'''<ref name="pmid14757604">{{cite journal| author=King VJ, Viswanathan M, Bordley WC, Jackman AM, Sutton SF, Lohr KN | display-authors=etal| title=Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. | journal=Arch Pediatr Adolesc Med | year= 2004 | volume= 158 | issue= 2 | pages= 127-37 | pmid=14757604 | doi=10.1001/archpedi.158.2.127 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14757604  }} </ref><br>    ❑ Supportive care such as [[hydration]], [[Saline|saline nasal drops]], nasal bulb suction<br>    ❑ Prevention includes [[Palivizumab]] for infants with the following conditions:
 
* [[Preterm birth]] less than 29 weeks gestation
Judicious use of laboratory testing, as previously discussed, can be helpful in confirming
* [[Prematurity|Chronic lung disease of prematurity]]
 
* Hemodynamically significant [[congenital heart disease]]|C02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Common Cold'''<ref name="urlTreatment of the Common Cold - American Family Physician">{{cite web |url=https://www.aafp.org/afp/2007/0215/p515.html |title=Treatment of the Common Cold - American Family Physician |format= |work= |accessdate=}}</ref><br>    ❑ Supportivr care such as [[hydration]], [[Saline|saline nasal drops]]<br>    ❑ Combination of over the counter medications such as [[antihistamines]], [[decongestants]], [[Cough suppressant|antitussives]], [[expectorants]], [[Mucolytic agent|mucolytics]], [[antipyretics]]/[[analgesics]]<br>    ❑ For [[fever]], [[acetaminophen]] (for children older than three months) or [[ibuprofen]] (for children older than six months)</div>
the diagnosis and allaying parental anxiety. Furthermore, in some conditions, cough is
 
an important component of the body’s natural response to the primary illness, and
 
suppressing the cough in the absence of effective therapy of the primary disorder may actually
 
worsen the problem.
 
Treatment of the underlying disorders causing cough is discussed in other sections of
 
this book; this chapter is limited to a review of medications used to treat cough itself. The
 
decision to use a cough medicine as an adjunct to the treatment of the primary disease is left
 
to the primary care physician and family. When cough is limiting or otherwise debilitating
 
the patient, symptomatic treatment may be attempted; however numerous studies question
 
whether over-the-counter cough preparations offer any significant clinical benefit.
 
In addition these cough and cold medications should not be given to children younger than
 
4 years because serious and potentially life-threatening side effects can occur from their
 
use. Finally, several studies have shown that honey may be beneficial in children older
 
than 2 years of age.
 
 
'''''Expectorants'''''
 
Expectorants such as guaifenesin (formerly known as glyceryl guaiacolate) may be used
 
in an attempt to make secretions more fluid and reduce sputum thickness, however the
 
effectiveness of this treatment has been called into question. This therapeutic approach


may be useful when drainage of secretions is important, as with sinusitis. Because expectorants
|C03=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Asthma'''<ref name="pmid7110806">{{cite journal| author=Ben-Zvi Z, Lam C, Hoffman J, Teets-Grimm KC, Kattan M| title=An evaluation of the initial treatment of acute asthma. | journal=Pediatrics | year= 1982 | volume= 70 | issue= 3 | pages= 348-53 | pmid=7110806 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7110806  }} </ref><ref name="pmid14555560">{{cite journal| author=Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C| title=Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. | journal=Chest | year= 2003 | volume= 124 | issue= 4 | pages= 1312-7 | pmid=14555560 | doi=10.1378/chest.124.4.1312 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14555560  }} </ref>
❑ Humidified oxygen by nasal cannula or facemask


work by increasing the fluid content of secretions, water is probably the most
❑ Inhaled short-acting beta-2 agonists (SABAs) such as (albuterol/salbutamol)
   
❑ Systemic glucocorticoids (Oral prednisone or dexamethasone)


effective expectorant. Saline nose sprays can make secretions more fluid and easily cleared
❑ ICU admission for severe exacerbation
*Systemic beta-agonists, methylxanthines, and magnesium sulfate
*noninvasive positive pressure ventilation and high-flow nasal cannula


by the patient and systemic hydration, but not overhydration, should always be optimized.
❑  Antibiotics for bacterial pneumonia or sinusitis


Despite widespread use, expectorants have not been shown to decrease cough in children.
|C04=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Pertussis'''<ref name="pmid15710944">{{cite journal| author=Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S| title=Diagnosis and management of pertussis. | journal=CMAJ | year= 2005 | volume= 172 | issue= 4 | pages= 509-15 | pmid=15710944 | doi=10.1503/cmaj.1040766 | pmc=548414 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15710944  }} </ref><ref name="pmid15048056">{{cite journal| author=Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R, CDC | display-authors=etal| title=Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. | journal=MMWR Recomm Rep | year= 2004 | volume= 53 | issue= RR-3 | pages= 1-36 | pmid=15048056 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15048056  }} </ref>


Other older expectorants, such as potassium iodide and ammonium chloride, are no
❑ Macrolides erythromycin, clarithromycin, and azithromycin are preferred for the treatment of pertussis in persons 1 month of age and older


longer prescribed to children because of their adverse effects when used at effective doses.
❑ Azithromycin remains the drug of choice for treatment or prophylaxis of pertussis in infants younger than 1 month of age,


❑ Monitor the infant for the development of infantile hypertrophic pyloric stenosis (IHPS) with the use of oral erythromycin and azithromycin


                   


❑ An alternative to macrolides is trimethoprim-sulfamethoxazole in infants 2 months of age and older




'''''Mucolytic Agents'''''
|C05=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Croup'''<ref name="pmid30133690">{{cite journal| author=Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW | display-authors=etal| title=Glucocorticoids for croup in children. | journal=Cochrane Database Syst Rev | year= 2018 | volume= 8 | issue=  | pages= CD001955 | pmid=30133690 | doi=10.1002/14651858.CD001955.pub4 | pmc=6513469 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30133690  }} </ref><ref name="pmid347921">{{cite journal| author=Westley CR, Cotton EK, Brooks JG| title=Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. | journal=Am J Dis Child | year= 1978 | volume= 132 | issue= 5 | pages= 484-7 | pmid=347921 | doi=10.1001/archpedi.1978.02120300044008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=347921  }} </ref><ref name="pmid8632929">{{cite journal| author=Klassen TP, Watters LK, Feldman ME, Sutcliffe T, Rowe PC| title=The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup. | journal=Pediatrics | year= 1996 | volume= 97 | issue= 4 | pages= 463-6 | pmid=8632929 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8632929  }} </ref>
❑ Comfort measures (keep the child calm as crying worsen airway obstruction


Acetylcysteine was previously used as a mucolytic agent to help liquefy thick secretions,
❑ A single dose of dexamethasone if symptoms persist for>3-5 days or worsen
❑ An inhaled epinephrine using a nebulizer for more severe symptoms


especially in diseases such as cystic fibrosis; however, its propensity for inducing airway
|C06=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Pneumonia'''<ref name="pmid21880587">{{cite journal| author=Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C | display-authors=etal| title=The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2011 | volume= 53 | issue= 7 | pages= e25-76 | pmid=21880587 | doi=10.1093/cid/cir531 | pmc=7107838 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21880587  }} </ref><ref name="pmid21903691">{{cite journal| author=Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M | display-authors=etal| title=British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. | journal=Thorax | year= 2011 | volume= 66 Suppl 2 | issue=  | pages= ii1-23 | pmid=21903691 | doi=10.1136/thoraxjnl-2011-200598 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21903691  }} </ref><ref name="pmid24615334">{{cite journal| author=Chang CC, Cheng AC, Chang AB| title=Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. | journal=Cochrane Database Syst Rev | year= 2014 | volume=  | issue= 3 | pages= CD006088 | pmid=24615334 | doi=10.1002/14651858.CD006088.pub4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24615334  }} </ref>
Inpatient treatment


reactivity and inflammation has lately made it less popular.
❑ Supportive care
*Antipyretics and/or analgesics (acetaminophen, ibuprofen)




'''''Cough Suppressants'''''
❑ Supplemental oxygen to maintain oxygen saturation ≥95 percent


Cough suppressants, which can be divided into peripheral and centrally acting agents,
❑ IV fluid therapy


can be effective in transiently decreasing cough severity and frequency. Peripheral agents
❑ IV empiric antibiotic treatment
* 1-6 months old (Ceftriaxone or Cefotaxime)
* ≥6 months (Ampicillin or penicillin G is preferred)
* For C. trachomatis, M. pneumoniae or C. pneumoniae (Azithromycin)


include demulcents (eg, throat lozenges), which soothe the throat, and topical anesthetics,
❑ For Severe pneumonia
* Ceftriaxone or Cefotaxime plus Macrolide (Azithromycin)


which can be sprayed or swallowed. Topical agents block the cough receptors, but their
❑ ICU admission
* Vancomycin plus Ceftriaxone or Cefotaxime  plus Azithromycin plus Antiviral if hospitalized during influenza season)


effects are short-lived because oral secretions rapidly wash them away. Centrally acting
❑ Complicated pneumonia
* Ceftriaxone or Cefotaxime plus Clindamycin if S. aureus or anaerobic is suspected


cough suppressants, including both narcotic and nonnarcotic medications, suppress


the cough reflex at the brain stem level. The narcotic agent most commonly used in
|C07=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Influenza'''<ref name="urlInfluenza Antiviral Medications: Summary for Clinicians | CDC">{{cite web |url=https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm |title=Influenza Antiviral Medications: Summary for Clinicians &#124; CDC |format= |work= |accessdate=}}</ref>


children is codeine. Although it has been shown to be effective in adults, studies on its
❑ Oral oseltamivir for:
*Hospitalized patients
*Patients with severe, complicated, or progressive illness
*Patients with risk factors for complications


safety and efficacy in children are lacking. Furthermore, data from adults should not be
}}
{{familytree/end}}


extrapolated to children, particularly those younger than 2 years, because the metabolic
===Chronic cough===
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | | | | | | A01 |A01=<div style="float: left; text-align: center; width: 10em; padding:1em;">'''Treat the underlying causes'''}}
{{familytree | | | | | | | | | | | | | |!| | | | | | }}
{{familytree | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| }}
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | }}
{{familytree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | C07 |
C01=<div style="float: left; text-align: left; width: 10em; padding:1em;"> '''Cough due to Cystic fibrosis'''<ref name="pmid31679946">{{cite journal| author=Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E | display-authors=etal| title=Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. | journal=Lancet | year= 2019 | volume= 394 | issue= 10212 | pages= 1940-1948 | pmid=31679946 | doi=10.1016/S0140-6736(19)32597-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31679946  }} </ref><ref name="pmid31253540">{{cite journal| author=Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J | display-authors=etal| title=A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. | journal=J Cyst Fibros | year= 2019 | volume= 18 | issue= 5 | pages= 708-713 | pmid=31253540 | doi=10.1016/j.jcf.2019.06.009 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31253540  }} </ref><ref name="pmid17761616">{{cite journal| author=Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB | display-authors=etal| title=Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. | journal=Am J Respir Crit Care Med | year= 2007 | volume= 176 | issue= 10 | pages= 957-69 | pmid=17761616 | doi=10.1164/rccm.200705-664OC | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17761616  }} </ref><ref name="pmid23540878">{{cite journal| author=Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB | display-authors=etal| title=Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. | journal=Am J Respir Crit Care Med | year= 2013 | volume= 187 | issue= 7 | pages= 680-9 | pmid=23540878 | doi=10.1164/rccm.201207-1160oe | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23540878  }} </ref>
❑ CFTR modulator such as tezacaftor-ivacaftor or lumacaftor-ivacaftor
*CFTR genotyping should be done first to determine the patient eligibility 
**Patients ≥12 years old with responsive CFTR mutations
**Younger patients with sufficient evidence for FDA approval
   
❑ Metered-dose Albuterol Inhaler
   
❑ Hypertonic saline


pathway for clearance of codeine is immature in infants. In older children, codeine should
❑ DNase such as dornase alfa
   
❑ Chest physiotherapy


still be avoided and only used in extreme cases and with very clear instructions because of
❑ Exercise
   
❑ Aerosolized antibiotics or long-acting antiasthmatics


the unpredictable and potentially dangerous variation of its metabolism in the pediatric
❑ Azithromycin
* Chronic treatment with for patients six years and older
|C02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Chronic bronchitis'''   


population. Other agents, such as hydrocodone, have no demonstrated advantage and
protracted bacterial bronchitis


pose a greater risk of dependency. Dextromethorphan (the dextro-isomer of codeine) is
❑  Augmentin (amoxicillin and clavulanate potassium) or Omnicef (cefdinir)
   
|C03=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Primary ciliary dyskinesia'''<ref name="pmid23796196">{{cite journal| author=Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW| title=Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. | journal=Am J Respir Crit Care Med | year= 2013 | volume= 188 | issue= 8 | pages= 913-22 | pmid=23796196 | doi=10.1164/rccm.201301-0059CI | pmc=3826280 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23796196  }} </ref><ref name="pmid25510893">{{cite journal| author=Hosie PH, Fitzgerald DA, Jaffe A, Birman CS, Rutland J, Morgan LC| title=Presentation of primary ciliary dyskinesia in children: 30 years' experience. | journal=J Paediatr Child Health | year= 2015 | volume= 51 | issue= 7 | pages= 722-6 | pmid=25510893 | doi=10.1111/jpc.12791 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25510893  }} </ref><ref name="pmid19948909">{{cite journal| author=Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G | display-authors=etal| title=Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. | journal=Eur Respir J | year= 2009 | volume= 34 | issue= 6 | pages= 1264-76 | pmid=19948909 | doi=10.1183/09031936.00176608 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19948909  }} </ref> 9387968


the most commonly used nonnarcotic antitussive; and despite data from adults, evidence
❑ Treatment should be individualized based on the clinical course of each patient


of efficacy for children is lacking.
❑ Supplemental oxygen for a few hours to days after birth for mild respiratory distress (tachypnea, mild hypoxemia)


Bronchiectasis


'''''Decongestants'''''
❑ Daily chest physiotherapy


Decongestants such as pseudoephedrine can be used either topically or systemically
❑ Oral antibiotics for acute exacerbation and it should be tailored based on the sputum culture results


to decrease nasal mucosal swelling. Decongestants can also facilitate sinus drainage by
❑ Preventive antibiotic therapy with Azithromycin may reduce the rate of exacerbations


decreasing sinus ostia obstruction, and may work well in combination with expectorants
* Do Sputum cultures prior to Azithromycin use to exclude nontuberculous mycobacteria infection
* Assess for risk of QT interval prolongation prior to Azithromycin use 


to optimize treatment of chronic sinusitis. Care should be taken in the use of these
❑ 


agents because they have been shown to lead to tachyarrhythmias in individuals who use
|C04=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Postnasal drib (Allergic Rhinitis)'''<ref name="pmid16428694">{{cite journal| author=Pratter MR| title=Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. | journal=Chest | year= 2006 | volume= 129 | issue= 1 Suppl | pages= 63S-71S | pmid=16428694 | doi=10.1378/chest.129.1_suppl.63S | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16428694  }} </ref>
❑ Antihistamines


them in excess. In addition, these agents have not been studied in children and should
❑ Nasal steroid sprays reduce swelling and inflammation of the nasal passages promoting proper drainage


be avoided in children younger than 2 years. Multiple reviews of the data from children
❑ Allergy shots (immunotherapy) if no improvement
   
❑ 
|C05=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Cough variant asthma'''<ref name="pmid2096171">{{cite journal| author=Pender ES, Pollack CV| title=Cough-variant asthma in children and adults: case reports and review. | journal=J Emerg Med | year= 1990 | volume= 8 | issue= 6 | pages= 727-31 | pmid=2096171 | doi=10.1016/0736-4679(90)90287-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2096171  }} </ref>
❑ Inhaler with albuterol, ipratropium, and/or inhaled steroids
   
|C06=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Recurrent viral bronchitis'''
❑ Antibiotics are not recommended except with chronic wet cough for ≥ 2-4 weeks, which could be mostly bacterial
❑ Albuterol or terbutaline inhalers
❑ corticosteroids if no improvement
❑ Stepped-up courses of inhaled corticosteroids might be effective
   
|C07=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cough due to Asthma'''<ref name="pmid11027739">{{cite journal| author=Childhood Asthma Management Program Research Group. Szefler S, Weiss S, Tonascia J, Adkinson NF, Bender B | display-authors=etal| title=Long-term effects of budesonide or nedocromil in children with asthma. | journal=N Engl J Med | year= 2000 | volume= 343 | issue= 15 | pages= 1054-63 | pmid=11027739 | doi=10.1056/NEJM200010123431501 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11027739  }} </ref><ref name="pmid18214538">{{cite journal| author=Jartti T| title=Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? | journal=Eur J Pediatr | year= 2008 | volume= 167 | issue= 7 | pages= 731-6 | pmid=18214538 | doi=10.1007/s00431-007-0644-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18214538  }} </ref>
Mild, persistent asthma
❑ low-dose, daily inhaled glucocorticoids 
❑ Daily leukotriene receptor antagonist (Montelukast )
* As an alternative to inhaled glucocorticoids 
* Limited use due to neuropsychiatric sede effects


between 2 and 6 years old also show lack of efficacy combined with a risk of side effects


in this age group. It is therefore recommended that these agents not be used in children
}}
 
{{familytree/end}}
younger than 6 years.
 
 
'''''Antihistamines'''''
 
Antihistamines, which can be helpful in the treatment of cough triggered by allergy, have
 
minimal effect when cough is the result of viral or bacterial infection and may actually be
 
detrimental because they can increase the thickness of secretions. First-generation H1-receptor
 
antagonists may decrease nasal drip by exerting an anticholinergic effect. Additionally,
 
diphenhydramine may have a modest direct effect on the medullary cough center. The
 
clinical benefits of these agents are unclear.
 
 
'''When to Refer'''
 
• Cough persists despite adequate therapy of primary disease
 
• Cough thought to be from hyperreactive airways is not easily reversible with _Beta-2 agonist
 
• Cough recurs more frequently than every 6 to 8 weeks
 
• Cough associated with failure to thrive
 
• Cough associated with other systemic illness
 
 
'''When to Admit'''
 
• Patient has respiratory distress
 
• Infant is unable to feed
 
• Cough is associated with bacterial pneumonia not responsive to oral antibiotic trial


==Do's==
==Do's==
 
* "For children aged less than 14-years with [[chronic cough]] (> 4 weeks duration) without an underlying lung disease but who have symptoms and signs or tests consistent with [[Gastroesophageal reflux|gastroesophageal pathological reflux]], they should be treated for [[GERD]] in accordance to evidence-based [[GERD]] specific guidelines (Grade 1B)." <ref name="pmid29470322">{{cite journal| author=Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F | display-authors=etal| title=Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. | journal=J Pediatr Gastroenterol Nutr | year= 2018 | volume= 66 | issue= 3 | pages= 516-554 | pmid=29470322 | doi=10.1097/MPG.0000000000001889 | pmc=5958910 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29470322  }} </ref><ref name="urlOverview | Gastro-oesophageal reflux disease in children and young people: diagnosis and management | Guidance | NICE">{{cite web |url=https://www.nice.org.uk/guidance/ng1 |title=Overview &#124; Gastro-oesophageal reflux disease in children and young people: diagnosis and management &#124; Guidance &#124; NICE |format= |work= |accessdate=}}</ref>
#Increase fluids
* "Children with chronic cough and typical symptoms of GERD should undergo medical treatment—dietary, lifestyle modifications and acid suppression therapy. A three-stage therapeutic trial should be completed before diagnosing reflux-related cough:<br>
#Rest in an upright position
:(1) clear-cut response to a 4 to 8-week treatment with PPI<br>
#add some humidity
:(2) relapse on stopping medication<br>
#Eliminate irritants<br />
:(3) new response to recommencing medication, with weaning down therapy as appropriate to the child’s symptoms." <ref name="pmid28882881">{{cite journal| author=de Benedictis FM, Bush A| title=Respiratory manifestations of gastro-oesophageal reflux in children. | journal=Arch Dis Child | year= 2018 | volume= 103 | issue= 3 | pages= 292-296 | pmid=28882881 | doi=10.1136/archdischild-2017-312890 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28882881  }} </ref>


==Don'ts==
==Don'ts==
* According to Chang et al., "for children aged less than 14-years with [[chronic cough]] (> 4 weeks duration) without an underlying lung disease, treatment for [[Gastroesophageal reflux disease|gastroesophageal reflux disease (GERD)]] should not be used when there are no clinical features of [[gastroesophageal reflux]] such as recurrent regurgitation, [[Dystonia|dystonic neck posturing]] in infants, or [[epigastric pain|heartburn/epigastric pain]] in older children (Grade1B)." <ref name="urljournal.chestnet.org">{{cite web |url=https://journal.chestnet.org/article/S0012-3692(19)30831-1/pdf |title=journal.chestnet.org |format= |work= |accessdate=}}</ref>
* For children aged less than 14-years with [[chronic cough]] (> 4 weeks duration) without an underlying lung disease but who have symptoms and signs or tests consistent with [[Gastroesophageal reflux|gastroesophageal pathological reflux]], [[Proton pump inhibitors|acid suppressive therapy]] should not be used solely for their [[chronic cough]] (Grade 1C). <ref name="urljournal.chestnet.org">{{cite web |url=https://journal.chestnet.org/article/S0012-3692(19)30831-1/pdf |title=journal.chestnet.org |format= |work= |accessdate=}}</ref>
* According to CHEST guidelines 2017, "For children aged less than 14-years with [[chronic cough]], basing the management on the etiology of the [[cough]] is recommended. An empirical approach aimed at treating [[Cough |upper airway cough syndrome]] due to a [[Rhinosinusitis|rhinosinus condition]], [[GERD]] and/or [[asthma]] should not be used unless other features consistent with these conditions are present." <ref name="pmid28143696">{{cite journal| author=Chang AB, Oppenheimer JJ, Weinberger MM, Rubin BK, Grant CC, Weir K | display-authors=etal| title=Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report. | journal=Chest | year= 2017 | volume= 151 | issue= 4 | pages= 884-890 | pmid=28143696 | doi=10.1016/j.chest.2017.01.025 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28143696  }} </ref>
* “In otherwise well children with nonspecific [[cough]], empirical [[H2-receptor antagonist|gastroesophageal reflux therapy]] is unlikely to be beneficial and is generally not recommended.” <ref name="pmid28882881">{{cite journal| author=de Benedictis FM, Bush A| title=Respiratory manifestations of gastro-oesophageal reflux in children. | journal=Arch Dis Child | year= 2018 | volume= 103 | issue= 3 | pages= 292-296 | pmid=28882881 | doi=10.1136/archdischild-2017-312890 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28882881  }} </ref>


==References==
{{Reflist|2}}


== References ==
[[Category:Up-To-Date]]
'''1.  Paediatrics signs and symptoms sorter_2<sup>nd</sup> ed'''
[[Category:Projects]]
 
[[Category:Resident survival guide]]
'''2.  Signs and symptoms in pediatric_AAP'''
[[Category:Pediatrics]]
 
[[Category:Primary care]]
'''3.  Nelson symptom based diagnosis'''
 
'''4.  Symptoms based diagnosis in pediatric_McGraw Hill'''

Latest revision as of 21:36, 1 March 2021



Resident
Survival
Guide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maysoon Fatahi, MD[2],Tayyaba Ali, M.D.[3], Huda A. Karman, M.D.

Synonyms and keywords: Cough in childhood, Cough in children, An approach to cough in children

Cough resident survival guide (pediatrics) Microchapters
Overview
Causes
Diagnosis
Treatment
Do's
Don'ts

Overview

Cough is a sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in a violent release of air from the lungs, and usually accompanied by a distinctive sound. A cough by itself is not a complete diagnosis but rather a symptom of an underlying condition, despite this, it accounts as one of the most common indications for visits to the general practitioners and family physicians with a good proportion of these cases resulting in a pulmonology referral. Coughing is an action the body takes to get rid of substances that are irritating the air passages. The act of coughing can be triggered by a myriad of conditions physiologic and otherwise. A cough is mostly initiated to clear a buildup of phlegm within the trachea. Coughing can also be triggered by a bolus of food entering the trachea and other parts of the respiratory tree rather than the esophagus due to a failure of the epiglottis function.

Causes

Life Threatening Causes

Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated:

Common Causes

Acute cough (less than 3 weeks)[4] Subacute (3 to 8 weeks) or chronic cough (3 to 4 months)[5]

Isolated cough: otherwise healthy child

Diagnosis

The approach to diagnosis of Cough in children is based on a step-wise testing strategy. Below is an algorithm summarising the identification and laboratory diagnosis of Cough.[6][7]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order Chest X-ray or spirometry (if child is able to perform)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider the diagnosis of Bacterial bronchitis
 
 
 
Consider the diagnosis of Asthma
❑ History of bilateral wheeze and exertional dyspnea
❑ Absence of other cough symptoms
❑ Absence of findings on lung examination
Reversible obstructive defect or normal finding on spirometry (if performed)
 
Consider the diagnosis of Retained foreign body
❑ History of choking or sudden onset of symptoms
❑ Monophonic or unilateral wheeze
❑ Chest X-ray finding suggesting foreign body
 
Consider the other type of cough
Tracheomalacia
Pertussis
Habit cough/ tic cough (typically absent at night or when distracted and may be honking or short/dry)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotics for 2 to 4 weeks
 
 
 
Trial of Asthma therapies for 2 to 4 weeks
 
 
Perform tests to confirm the diagnosis and treat as appropriate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cough resolves
❑ Likely bacterial bronchitis
❑ Reassess in 3 to 4 months to confirm that child remains well
 
Productive cough continues after 4 weeks
❑ Consider the diagnosis of:
 
Asthma Improved
❑ Continue treatment
Asthma not improved
❑ Reassess for other causes of cough
 
No foreign body
❑ Reassess for other causes of cough

Treatment

Shown below is an algorithm summarizing the treatment of underlying conditions that cause cough.

Acute cough

 
 
 
 
 
 
 
 
 
 
 
 
Treat the underlying causes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cough due to Bronchiolitis[8]
❑ Supportive care such as hydration, saline nasal drops, nasal bulb suction
❑ Prevention includes Palivizumab for infants with the following conditions:
 
Cough due to Common Cold[9]
❑ Supportivr care such as hydration, saline nasal drops
❑ Combination of over the counter medications such as antihistamines, decongestants, antitussives, expectorants, mucolytics, antipyretics/analgesics
❑ For fever, acetaminophen (for children older than three months) or ibuprofen (for children older than six months)
 
Cough due to Asthma[10][11]

❑ Humidified oxygen by nasal cannula or facemask

❑ Inhaled short-acting beta-2 agonists (SABAs) such as (albuterol/salbutamol)

❑ Systemic glucocorticoids (Oral prednisone or dexamethasone)

❑ ICU admission for severe exacerbation

  • Systemic beta-agonists, methylxanthines, and magnesium sulfate
  • noninvasive positive pressure ventilation and high-flow nasal cannula

❑ Antibiotics for bacterial pneumonia or sinusitis

 
Cough due to Pertussis[12][13]

❑ Macrolides erythromycin, clarithromycin, and azithromycin are preferred for the treatment of pertussis in persons 1 month of age and older

❑ Azithromycin remains the drug of choice for treatment or prophylaxis of pertussis in infants younger than 1 month of age,

❑ Monitor the infant for the development of infantile hypertrophic pyloric stenosis (IHPS) with the use of oral erythromycin and azithromycin


❑ An alternative to macrolides is trimethoprim-sulfamethoxazole in infants 2 months of age and older
 
Cough due to Croup[14][15][16]

❑ Comfort measures (keep the child calm as crying worsen airway obstruction

❑ A single dose of dexamethasone if symptoms persist for>3-5 days or worsen

❑ An inhaled epinephrine using a nebulizer for more severe symptoms
 
Cough due to Pneumonia[17][18][19]

Inpatient treatment

❑ Supportive care

  • Antipyretics and/or analgesics (acetaminophen, ibuprofen)


❑ Supplemental oxygen to maintain oxygen saturation ≥95 percent

❑ IV fluid therapy

❑ IV empiric antibiotic treatment

  • 1-6 months old (Ceftriaxone or Cefotaxime)
  • ≥6 months (Ampicillin or penicillin G is preferred)
  • For C. trachomatis, M. pneumoniae or C. pneumoniae (Azithromycin)

❑ For Severe pneumonia

  • Ceftriaxone or Cefotaxime plus Macrolide (Azithromycin)

❑ ICU admission

  • Vancomycin plus Ceftriaxone or Cefotaxime plus Azithromycin plus Antiviral if hospitalized during influenza season)

❑ Complicated pneumonia

  • Ceftriaxone or Cefotaxime plus Clindamycin if S. aureus or anaerobic is suspected
 
Cough due to Influenza[20]

❑ Oral oseltamivir for:

  • Hospitalized patients
  • Patients with severe, complicated, or progressive illness
  • Patients with risk factors for complications

Chronic cough

 
 
 
 
 
 
 
 
 
 
 
 
Treat the underlying causes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cough due to Cystic fibrosis[21][22][23][24]

❑ CFTR modulator such as tezacaftor-ivacaftor or lumacaftor-ivacaftor

  • CFTR genotyping should be done first to determine the patient eligibility
    • Patients ≥12 years old with responsive CFTR mutations
    • Younger patients with sufficient evidence for FDA approval

❑ Metered-dose Albuterol Inhaler

❑ Hypertonic saline

❑ DNase such as dornase alfa

❑ Chest physiotherapy

❑ Exercise

❑ Aerosolized antibiotics or long-acting antiasthmatics

❑ Azithromycin

  • Chronic treatment with for patients six years and older
 
Cough due to Chronic bronchitis

protracted bacterial bronchitis

❑ Augmentin (amoxicillin and clavulanate potassium) or Omnicef (cefdinir)

 
Cough due to Primary ciliary dyskinesia[25][26][27] 9387968

❑ Treatment should be individualized based on the clinical course of each patient

❑ Supplemental oxygen for a few hours to days after birth for mild respiratory distress (tachypnea, mild hypoxemia)

Bronchiectasis

❑ Daily chest physiotherapy

❑ Oral antibiotics for acute exacerbation and it should be tailored based on the sputum culture results

❑ Preventive antibiotic therapy with Azithromycin may reduce the rate of exacerbations

  • Do Sputum cultures prior to Azithromycin use to exclude nontuberculous mycobacteria infection
  • Assess for risk of QT interval prolongation prior to Azithromycin use
 
Cough due to Postnasal drib (Allergic Rhinitis)[28]

❑ Antihistamines

❑ Nasal steroid sprays reduce swelling and inflammation of the nasal passages promoting proper drainage

❑ Allergy shots (immunotherapy) if no improvement

 
Cough due to Cough variant asthma[29]

❑ Inhaler with albuterol, ipratropium, and/or inhaled steroids

 
Cough due to Recurrent viral bronchitis

❑ Antibiotics are not recommended except with chronic wet cough for ≥ 2-4 weeks, which could be mostly bacterial ❑ Albuterol or terbutaline inhalers ❑ corticosteroids if no improvement ❑ Stepped-up courses of inhaled corticosteroids might be effective ❑

 
Cough due to Asthma[30][31]

Mild, persistent asthma ❑ low-dose, daily inhaled glucocorticoids ❑ Daily leukotriene receptor antagonist (Montelukast )

  • As an alternative to inhaled glucocorticoids
  • Limited use due to neuropsychiatric sede effects

Do's

  • "For children aged less than 14-years with chronic cough (> 4 weeks duration) without an underlying lung disease but who have symptoms and signs or tests consistent with gastroesophageal pathological reflux, they should be treated for GERD in accordance to evidence-based GERD specific guidelines (Grade 1B)." [32][33]
  • "Children with chronic cough and typical symptoms of GERD should undergo medical treatment—dietary, lifestyle modifications and acid suppression therapy. A three-stage therapeutic trial should be completed before diagnosing reflux-related cough:
(1) clear-cut response to a 4 to 8-week treatment with PPI
(2) relapse on stopping medication
(3) new response to recommencing medication, with weaning down therapy as appropriate to the child’s symptoms." [34]

Don'ts

References

  1. Patocka C, Nemeth J (2012). "Pulmonary embolism in pediatrics". J Emerg Med. 42 (1): 105–16. doi:10.1016/j.jemermed.2011.03.006. PMID 21530139.
  2. Tan TQ, Mason EO, Wald ER, Barson WJ, Schutze GE, Bradley JS; et al. (2002). "Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae". Pediatrics. 110 (1 Pt 1): 1–6. doi:10.1542/peds.110.1.1. PMID 12093940.
  3. "Acute Asthma: Observations Regarding the Management of a Pediatric Emergency Room | American Academy of Pediatrics".
  4. 4.0 4.1 "www.ncbi.nlm.nih.gov" (PDF).
  5. 5.0 5.1 de Jongste JC, Shields MD (2003). "Cough . 2: Chronic cough in children". Thorax. 58 (11): 998–1003. doi:10.1136/thorax.58.11.998. PMC 1746521. PMID 14586058.
  6. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S; et al. (2017). "Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure". Eur Respir J. 50 (2). doi:10.1183/13993003.02426-2016. PMID 28860265.
  7. Weinberger M, Hoegger M (2016). "The cough without a cause: Habit cough syndrome". J Allergy Clin Immunol. 137 (3): 930–1. doi:10.1016/j.jaci.2015.09.002. PMID 26483178.
  8. King VJ, Viswanathan M, Bordley WC, Jackman AM, Sutton SF, Lohr KN; et al. (2004). "Pharmacologic treatment of bronchiolitis in infants and children: a systematic review". Arch Pediatr Adolesc Med. 158 (2): 127–37. doi:10.1001/archpedi.158.2.127. PMID 14757604.
  9. "Treatment of the Common Cold - American Family Physician".
  10. Ben-Zvi Z, Lam C, Hoffman J, Teets-Grimm KC, Kattan M (1982). "An evaluation of the initial treatment of acute asthma". Pediatrics. 70 (3): 348–53. PMID 7110806.
  11. Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C (2003). "Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial". Chest. 124 (4): 1312–7. doi:10.1378/chest.124.4.1312. PMID 14555560.
  12. Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S (2005). "Diagnosis and management of pertussis". CMAJ. 172 (4): 509–15. doi:10.1503/cmaj.1040766. PMC 548414. PMID 15710944.
  13. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R, CDC; et al. (2004). "Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee". MMWR Recomm Rep. 53 (RR-3): 1–36. PMID 15048056.
  14. Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW; et al. (2018). "Glucocorticoids for croup in children". Cochrane Database Syst Rev. 8: CD001955. doi:10.1002/14651858.CD001955.pub4. PMC 6513469 Check |pmc= value (help). PMID 30133690.
  15. Westley CR, Cotton EK, Brooks JG (1978). "Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study". Am J Dis Child. 132 (5): 484–7. doi:10.1001/archpedi.1978.02120300044008. PMID 347921.
  16. Klassen TP, Watters LK, Feldman ME, Sutcliffe T, Rowe PC (1996). "The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup". Pediatrics. 97 (4): 463–6. PMID 8632929.
  17. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C; et al. (2011). "The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America". Clin Infect Dis. 53 (7): e25–76. doi:10.1093/cid/cir531. PMC 7107838 Check |pmc= value (help). PMID 21880587.
  18. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M; et al. (2011). "British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011". Thorax. 66 Suppl 2: ii1–23. doi:10.1136/thoraxjnl-2011-200598. PMID 21903691.
  19. Chang CC, Cheng AC, Chang AB (2014). "Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults". Cochrane Database Syst Rev (3): CD006088. doi:10.1002/14651858.CD006088.pub4. PMID 24615334.
  20. "Influenza Antiviral Medications: Summary for Clinicians | CDC".
  21. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E; et al. (2019). "Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial". Lancet. 394 (10212): 1940–1948. doi:10.1016/S0140-6736(19)32597-8. PMID 31679946.
  22. Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J; et al. (2019). "A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis". J Cyst Fibros. 18 (5): 708–713. doi:10.1016/j.jcf.2019.06.009. PMID 31253540.
  23. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB; et al. (2007). "Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health". Am J Respir Crit Care Med. 176 (10): 957–69. doi:10.1164/rccm.200705-664OC. PMID 17761616.
  24. Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB; et al. (2013). "Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health". Am J Respir Crit Care Med. 187 (7): 680–9. doi:10.1164/rccm.201207-1160oe. PMID 23540878.
  25. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW (2013). "Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease". Am J Respir Crit Care Med. 188 (8): 913–22. doi:10.1164/rccm.201301-0059CI. PMC 3826280. PMID 23796196.
  26. Hosie PH, Fitzgerald DA, Jaffe A, Birman CS, Rutland J, Morgan LC (2015). "Presentation of primary ciliary dyskinesia in children: 30 years' experience". J Paediatr Child Health. 51 (7): 722–6. doi:10.1111/jpc.12791. PMID 25510893.
  27. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G; et al. (2009). "Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children". Eur Respir J. 34 (6): 1264–76. doi:10.1183/09031936.00176608. PMID 19948909.
  28. Pratter MR (2006). "Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines". Chest. 129 (1 Suppl): 63S–71S. doi:10.1378/chest.129.1_suppl.63S. PMID 16428694.
  29. Pender ES, Pollack CV (1990). "Cough-variant asthma in children and adults: case reports and review". J Emerg Med. 8 (6): 727–31. doi:10.1016/0736-4679(90)90287-6. PMID 2096171.
  30. Childhood Asthma Management Program Research Group. Szefler S, Weiss S, Tonascia J, Adkinson NF, Bender B; et al. (2000). "Long-term effects of budesonide or nedocromil in children with asthma". N Engl J Med. 343 (15): 1054–63. doi:10.1056/NEJM200010123431501. PMID 11027739.
  31. Jartti T (2008). "Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?". Eur J Pediatr. 167 (7): 731–6. doi:10.1007/s00431-007-0644-3. PMID 18214538.
  32. Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F; et al. (2018). "Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition". J Pediatr Gastroenterol Nutr. 66 (3): 516–554. doi:10.1097/MPG.0000000000001889. PMC 5958910. PMID 29470322.
  33. "Overview | Gastro-oesophageal reflux disease in children and young people: diagnosis and management | Guidance | NICE".
  34. 34.0 34.1 de Benedictis FM, Bush A (2018). "Respiratory manifestations of gastro-oesophageal reflux in children". Arch Dis Child. 103 (3): 292–296. doi:10.1136/archdischild-2017-312890. PMID 28882881.
  35. 35.0 35.1 "journal.chestnet.org".
  36. Chang AB, Oppenheimer JJ, Weinberger MM, Rubin BK, Grant CC, Weir K; et al. (2017). "Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report". Chest. 151 (4): 884–890. doi:10.1016/j.chest.2017.01.025. PMID 28143696.